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EDITORIAL
Repairing renal lesions: Will VEGF be the builder?
Vascular endothelial growth factor (VEGF)—also end-organ microvasculature [17]. Lesions of these syn-
known as vascular permeability factor—is a member of a dromes called hemolytic uremic syndrome or thrombotic
family of heparin-binding growth factors with significant thrombocytopenic purpura—depending on whether re-
roles in angiogenesis, tumor growth, and development nal or brain lesions prevail—consist of thickening of arte-
[1–3]. It is a dimeric glycoprotein arising from alternative rioles and capillary walls, with swelling and detachment
splicing of the VEGF mRNA into five isoforms (VEGF121, of the endothelium from the basement membrane [17].
VEGF145, VEGF165, VEGF189, VEGF206), of which VEGF121 Hemolytic uremic syndrome, a disease mostly affecting
and VEGF165 are soluble secreted forms, while VEGF189 children, manifests as a consequence of an Escherichia
and VEGF206 are mostly bound to the cell surface or to coli intestinal infection [17]. Although 80 to 90% of af-
extracellular matrix [4, 5]. VEGF has three identified re- fected children recover kidney function after initial renal
ceptors: tyrosine kinase flt-1 [6], KDR tyrosine kinase [7], insufficiency, a substantial percentage of them are left
and the recently identified neurofilin-1, which enhances with residual proteinuria that may increase with time to
binding of VEGF165 to KDR [8]. the point that end-stage renal failure develops some 15
In normal human kidneys, VEGF is expressed mainly to 25 years after the initial diagnosis [17]. The severity
on the podocytes and tubular epithelial cells of distal of the initial injury dictates long-term outcome. Patients
and collecting ducts [9] besides peritubular capillaries with prolonged anuria have the worse long-term progno-
where VEGF actually binds preferentially [10]. Expres- sis [17]. Whether VEGF, which stimulates endothelial
sion of flt-1, KDR and neurofilin-1 receptor were found cell growth to form new vessels, could enhance the recov-
on mesangial cells [11]. Because of receptor distribution ery of hemolytic uremic syndrome and reduce long-term
and due to the fact that VEGF targets preferentially— sequelae was a smart hypothesis to test. Lesions reminis-
albeit not solely—endothelial cells, the possibility that
cent of those in human hemolytic uremic syndrome were
VEGF plays a pivotal role on glomerular permselectivity
induced in rats by giving an anti-endothelial cell antibodyand regulated endothelial and mesangial cell growth [12]
into the renal artery, which produced loss of glomerularin health and disease has been extensively explored. Ani-
and peritubular capillary endothelium and decreased ar-mals with mesangioproliferative nephritis [13] and exper-
teriolar density [16]. Those animals also given subcutane-imentally induced diabetes [14] show evidence of VEGF
ous VEGF121 the day after injury was induced were moreand specific receptor up-regulation. The same trend to
protected than controls having a higher number of glo-increased local production of VEGF and its receptor ex-
meruli with an intact endothelium. Concomitantly, bloodpression has been found in human proliferative glomeru-
vessel density increased by VEGF treatment. At the endlonephritis [15]. Thus, there are reasons to suspect that
of the observation period VEGF121-treated animals alsoVEGF forming enzymes and receptor pathways are acti-
had less interstitial fibrosis and cortical atrophy and theirvated during renal injury. Would this imply that VEGF
renal function was better preserved. Admittedly, sometakes an active part in the pathophysiology of renal dam-
spontaneous capillary repair also had occurred in kid-age or rather, does it contribute to lesion resolution?
neys given vehicle, but benefit in VEGF121-treated ratsThe answer to this question is perhaps more complex
was superior, implicating active microvascular repair andthat one would think. Hopefully, the study of Kim et al
maybe even new vessel formation. Direct evidence thatin this issue of Kidney International, showing that VEGF
injected VEGF was actually angiogenic was not providedserves to limit thrombotic microangiopathy, represents
in the article. A previous study, however, has convinc-an important contribution to the matter [16]. Acute loss
ingly documented that VEGF may play a distinct role inof VEGF in the outer medullary tubules soon after the
small vessel repair after a given injury to the kidney [18].induction of the disease [16] suggested to the authors that
Thus, in rats with mesangioproliferative nephritis thegiving exogenous VEGF could be beneficial. Thrombotic
microangiopathies are syndromes of hemolytic anemia VEGF165 aptamer, an antagonist of VEGF [19], reduced
and thrombocytopenia with platelet thrombi formed in glomerular endothelial regeneration and increased cell
death. It would be important to know the relative po-
tency of VEGF121 and VEGF165 in inducing microvascular
protection in the two models and why Kim et al choseÓ 2000 by the International Society of Nephrology
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